Drugmaker Barr Pharmaceuticals ( BRL) said Friday that it made all the required filings with the U.S. Federal Trade Commission and German regulators regarding its proposed acquisition of Pliva, a generic drugmaker based in Croatia.

Barr has offered about $2.3 billion for Pliva, but Iceland's Actavis Group is also trying to buy the company for the same amount.

''We are hoping for an expedited review and intend to pursue the issuance of our formal tender offer to acquire Pliva in accordance with Croatian takeover law and the Croatian Financial Services Supervisory Agency's instructions as expeditiously as possible," Barr, of Woodcliff Lake, N.J., said in a press release.

Shares of Barr were down 42 cents, or 0.9%, at $46.96.
This story was created through a joint venture between TheStreet.com and IRIS.